AR/PARP Dual-Targeting Bioactive Photosensitizer for Photo-Immunotherapy of Prostate Cancer.

Authors

Zhifang Yang, Minjia Wang, Qiyu Chen, Kai Zhang, Minqi Zhou, Hongyu Li, Jiapei Yang, Yingjian Zhu, Tao Shen, Ling Li, Leilei Shi

Published in

Advanced materials (Deerfield Beach, Fla.). Pages e74964. Sep 09, 2026. Epub Sep 09, 2026.

Abstract

Prostate cancer poses a severe threat to men's health worldwide, and conventional therapeutic modalities are associated with various limitations. Photodynamic therapy (PDT) offers distinctive advantages such as minimal invasiveness, mild side effects and repeatable treatment. However, the therapeutic efficacy of PDT is limited by two critical factors: the single functional property of traditional photosensitizers and the pathological tumor microenvironment. Accordingly, molecular targeting photosensitizers have been developed to address these drawbacks. Notably, long-term administration of single-target agents entails a high risk of drug resistance. Accordingly, based on two key targets closely implicated in the DNA repair pathways of prostate cancer cells, the androgen receptor (AR), and poly(ADP-ribose) polymerase (PARP), we proposed an AR/PARP dual-targeting photosensitizer strategy and synthesized a quinoxalinone-based photosensitizer QTEO, which can simultaneously target AR and PARP and exert a synergistic effect with photodynamic activity to induce DNA damage in cancer cells. The resulting damaged DNA fragments can further activate the innate immune pathways of the organism through a coordinated cascade of reactions. This promising strategy concurrently overcomes the limited functionality of conventional photosensitizers, the potential drug resistance induced by single-target agents, and the complex pharmacokinetic issues associated with multidrug combination therapy, ultimately enabling molecular-targeting photo-immunotherapy for prostate cancer.

PMID:
42714307
Bibliographic data and abstract were imported from PubMed on 09 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.